Neoplasms, Second Primary
"Neoplasms, Second Primary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Descriptor ID |
D016609
|
MeSH Number(s) |
C04.692
|
Concept/Terms |
Neoplasms, Second Primary- Neoplasms, Second Primary
- Neoplasm, Second Primary
- Second Primary Neoplasm
- Metachronous Second Primary Neoplasms
- Neoplasms, Metachronous
- Second Primary Neoplasms, Metachronous
- Second Malignancy
- Malignancies, Second
- Malignancy, Second
- Second Malignancies
- Second Neoplasm
- Neoplasm, Second
- Neoplasms, Second
- Second Neoplasms
- Second Primary Neoplasms
- Metachronous Neoplasms
- Metachronous Neoplasm
- Neoplasm, Metachronous
- Neoplasms, Metachronous Second Primary
Neoplasms, Therapy-Associated- Neoplasms, Therapy-Associated
- Neoplasm, Therapy-Associated
- Neoplasms, Therapy Associated
- Therapy-Associated Neoplasm
- Neoplasms, Treatment-Associated
- Neoplasm, Treatment-Associated
- Neoplasms, Treatment Associated
- Treatment-Associated Neoplasm
- Neoplasms, Treatment-Related
- Neoplasm, Treatment-Related
- Neoplasms, Treatment Related
- Treatment-Related Neoplasm
- Therapy-Related Neoplasms
- Therapy Related Neoplasms
- Treatment-Associated Neoplasms
- Treatment Associated Neoplasms
- Treatment-Related Neoplasms
- Treatment Related Neoplasms
- Neoplasms, Therapy-Related
- Neoplasm, Therapy-Related
- Neoplasms, Therapy Related
- Therapy-Related Neoplasm
- Therapy-Associated Neoplasms
- Therapy Associated Neoplasms
Therapy-Associated Cancer- Therapy-Associated Cancer
- Cancer, Therapy-Associated
- Cancers, Therapy-Associated
- Therapy Associated Cancer
- Therapy-Associated Cancers
- Therapy-Related Cancer
- Cancer, Therapy-Related
- Cancers, Therapy-Related
- Therapy Related Cancer
- Therapy-Related Cancers
- Treatment-Related Cancer
- Cancer, Treatment-Related
- Cancers, Treatment-Related
- Treatment Related Cancer
- Treatment-Related Cancers
- Treatment-Associated Cancer
- Cancer, Treatment-Associated
- Cancers, Treatment-Associated
- Treatment Associated Cancer
- Treatment-Associated Cancers
Cancer, Second Primary- Cancer, Second Primary
- Cancers, Second Primary
- Second Primary Cancer
- Second Primary Cancers
- Second Cancer
- Cancer, Second
- Cancers, Second
- Second Cancers
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Second Primary".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Second Primary".
This graph shows the total number of publications written about "Neoplasms, Second Primary" by people in this website by year, and whether "Neoplasms, Second Primary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 0 | 1 | 1 |
1996 | 5 | 0 | 5 |
1997 | 0 | 1 | 1 |
1998 | 2 | 0 | 2 |
1999 | 5 | 3 | 8 |
2000 | 5 | 5 | 10 |
2001 | 1 | 0 | 1 |
2002 | 3 | 0 | 3 |
2003 | 4 | 0 | 4 |
2004 | 5 | 2 | 7 |
2005 | 5 | 1 | 6 |
2006 | 4 | 5 | 9 |
2007 | 2 | 2 | 4 |
2008 | 4 | 1 | 5 |
2009 | 5 | 4 | 9 |
2010 | 5 | 2 | 7 |
2011 | 5 | 0 | 5 |
2012 | 5 | 3 | 8 |
2013 | 3 | 0 | 3 |
2014 | 5 | 2 | 7 |
2015 | 7 | 0 | 7 |
2016 | 8 | 1 | 9 |
2017 | 8 | 0 | 8 |
2018 | 2 | 0 | 2 |
2019 | 6 | 0 | 6 |
2020 | 5 | 0 | 5 |
2021 | 7 | 0 | 7 |
2022 | 6 | 0 | 6 |
2023 | 3 | 0 | 3 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Second Primary" by people in Profiles.
-
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024 Jan 02; 7(1):e2350903.
-
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735.
-
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 11 01; 30(11).
-
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. Clin Cancer Res. 2023 01 04; 29(1):110-121.
-
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576.
-
Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. Br J Haematol. 2023 02; 200(4):489-493.
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
-
cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clin Cancer Res. 2022 05 02; 28(9):1841-1853.
-
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744.
-
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022 06 10; 40(17):1939-1948.